Trt-Gln | 47606-67-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: Trt-Gln
• 英文别名: Fmoc-Gln(Trt)-OH；N²-trityl-L-glutamine；N-Trityl-L-glutaminsaeure-5-amid；N²-Trityl-L-glutamin；N-Trityl-L-glutamin；(2S)-5-amino-5-oxo-2-(tritylazaniumyl)pentanoate
• CAS: 47606-67-7
• 化学式: C₂₄H₂₄N₂O₃
• 分子量: 388.466
• InChiKey: YYDGZQRGAMRHNE-NRFANRHFSA-N

物化性质

• 沸点：
  628.0±55.0 °C(Predicted)
• 密度：
  1.214±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  29
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  92.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Trt-Gln 在 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 为溶剂， 反应 21.83h， 生成 Trt-Gln-Phe-OBzl
  参考文献：
  名称：

  Cordopatis, Paul; Manessi-Zoupa, Evy; Theodoropoulos, Dimitrios, Collection of Czechoslovak Chemical Communications, 1990, vol. 55, # 10, p. 2575 - 2579

  摘要：

  DOI：
• 作为产物：
  描述：

  N-trityl-L-glutamic acid 5-methyl ester 在 甲醇 、 氨 作用下， 生成 Trt-Gln
  参考文献：
  名称：

  Amiard; Heymes, Bulletin de la Societe Chimique de France, 1957, p. 1373,1378

  摘要：

  DOI：

文献信息

• [EN] REDOX DEHYDRATION COUPLING CATALYSTS AND METHODS RELATED THERETO<br/>[FR] CATALYSEURS DE COUPLAGE DE DÉSHYDRATATION RÉDOX ET PROCÉDÉS ASSOCIÉS À CEUX-CI
  申请人：UNIV EMORY

  公开号：WO2017070157A1

  公开（公告）日：2017-04-27

  This disclosure relates to synthetic coupling methods using catalytic molecules. In certain embodiments, the catalytic molecules comprise heterocyclic thiolamide, S-acylthiosalicylamide, disulfide, selenium containing heterocycle, diselenide compound, ditelluride compound or tellurium containing heterocycle. Catalytic molecules disclosed herein are useful as catalysts in the transformation of hydroxy group containing compounds to amides, esters, ketones, and other carbon to heteroatom or carbon to carbon transformations.

  这份披露涉及使用催化分子的合成偶联方法。在某些实施例中，这些催化分子包括杂环硫酰胺、S-酰基硫代水杨酰胺、二硫化物、含硒杂环、二硒化合物、二碲化合物或含碲杂环。本文披露的催化分子可用作催化剂，用于将含羟基化合物转化为酰胺、酯、酮和其他碳到杂原子或碳到碳的转化过程中。
• 5-Methylisoxazole-3-carboxamide-Directed Palladium-Catalyzed γ-C(sp³)–H Acetoxylation and Application to the Synthesis of γ-Mercapto Amino Acids for Native Chemical Ligation
  作者：Kalyan Kumar Pasunooti、Renliang Yang、Biplab Banerjee、Terence Yap、Chuan-Fa Liu

  DOI：10.1021/acs.orglett.6b01160

  日期：2016.6.3

  Palladium-catalyzed acetoxylation of the primary γ-C(sp3)–H bonds in the amino acids Val, Thr, and Ile was achieved using a newly discovered 5-methylisoxazole-3-carboxamide directing group. The γ-acetoxylated α-amino acid derivatives could be easily converted to γ-mercapto amino acids, which are useful for native chemical ligation (NCL). The first application of NCL at isoleucine in the semisynthesis

  使用新发现的5-甲基异恶唑-3-羧酰胺指导基团实现了氨基酸Val，Thr和Ile中钯的初级γ-C（sp 3）–H键的钯催化乙酰氧基化。γ-乙酰氧基化的α-氨基酸衍生物可以轻松转换为γ-巯基氨基酸，可用于天然化学连接（NCL）。还展示了NCL在异亮氨酸在非洲爪蟾组蛋白H3蛋白半合成中的首次应用。
• [EN] PEPTIDES AS OXYTOCIN AGONISTS<br/>[FR] PEPTIDES UTILISÉS EN TANT QU'AGONISTES D'OXYTOCINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015185467A1

  公开（公告）日：2015-12-10

  The invention relates to compounds of formula (I), wherein R1 is hydrogen, lower alkyl or cycloalkyl; R2 is hydrogen or R1 and R 2 may form together with the N and C atom to which they are attached a pyrrolidine ring optionally substituted by one or two F-atoms or by hydroxy, or may form an azetidine or a piperazine ring; R3 is hydrogen, lower alkyl, lower alkyl substituted by hydroxy, -(CH2)2C(O)NH2, benzyl, phenyl, -CH2-five membered aromatic heterocyclic group, CH2-indolyl, -CH2-cycloalkyl, cycloalkyl or -(CH2)2-S-lower alkyl; R3' is hydrogen or lower alkyl; or X is -C(0)-CHR4-CHR4 -C(0)-NH-CH2- R4/R4 are hydrogen or one of R4 or R4 is amino: o is 0 or 1; or to pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. It has been found that the present compounds are oxytocin receptor agonists for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawel, drug addiction and for the treatment of Prader-Willi Syndrom.

  该发明涉及化合物的结构式(I)，其中R1为氢、较低的烷基或环烷基；R2为氢或者R1和R2可以与它们连接的N和C原子一起形成一个可选由一个或两个F原子或羟基取代的吡咯烷环，或者可以形成一个氮杂环或一个哌嗪环；R3为氢、较低的烷基、羟基取代的较低烷基、-(CH2)2C(O)NH2、苄基、苯基、-CH2-五元芳香杂环基、CH2-吲哚基、-CH2-环烷基、环烷基或-(CH2)2-S-较低烷基；R3'为氢或较低的烷基；或X为-C(0)-CHR4-CHR4 -C(0)-NH-CH2-，R4/R4为氢或R4或R4中的一个为氨基；o为0或1；或其药学上可接受的酸盐、消旋混合物或其相应的对映体和/或光学异构体。已发现这些化合物是催产素受体激动剂，用于治疗自闭症、压力，包括创伤后应激障碍、焦虑症，包括焦虑症和抑郁症、精神分裂症、精神障碍和记忆丧失、酒精戒断、药物成瘾以及普拉德-威利综合症的治疗。
• Proteomic analysis
  申请人：The Scripps Research Institute of an Assignment

  公开号：US20020064799A1

  公开（公告）日：2002-05-30

  The present invention provides methods for analyzing proteomes, as cells or lysates. The analysis is based on the use of probes that have specificity to the active form of proteins, particularly enzymes and receptors. The probes can be identified in different ways. In accordance with the present invention, a method is provided for generating and screening compound libraries that are used for the identification of lead molecules, and for the parallel identification of their biological targets. By appending specific functionalities and/or groups to one or more binding moieties, the reactive functionalities gain binding affinity and specificity for particular proteins and classes of proteins. Such libraries of candidate compounds, referred to herein as activity-based probes, or ABPs, are used to screen for one or more desired biological activities or target proteins.

  本发明提供了用于分析蛋白质组的方法，例如细胞或裂解物。该分析基于具有特异性对蛋白质的活性形式的探针的使用，特别是酶和受体。这些探针可以通过不同的方式进行识别。根据本发明，提供了一种用于生成和筛选化合物库的方法，用于识别引物分子，并并行识别它们的生物学靶标。通过向一个或多个结合基团添加特定的功能性和/或基团，反应性功能性获得了对特定蛋白质和蛋白质类的结合亲和性和特异性。这种候选化合物库，本文称为活性探针（ABPs），用于筛选一个或多个所需的生物活性或靶标蛋白质。
• PEPTIDES AS OXYTOCIN AGONISTS
  申请人：Hoffmann-La Roche Inc.

  公开号：US20170081368A1

  公开（公告）日：2017-03-23

  The present compounds are oxytocin receptor agonists for the treatment of autism, stress, including post-traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of Prader-Willi Syndrome.

  目前的化合物是催产素受体激动剂，用于治疗自闭症、压力（包括创伤后应激障碍）、焦虑（包括焦虑症和抑郁症）、精神分裂症、精神障碍和记忆丧失、酒精戒断、药物成瘾以及普拉德-威利综合征。